An observational study in Radiation Toxicity, sponsored by Centro di Riferimento Oncologico - Aviano. Recruiting at 1 site in Italy. Per ClinicalTrials.gov, last updated 2024-10-15.
Sponsored by Centro di Riferimento Oncologico - Aviano · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Radiation Injuries with a site in Italy — 7 open to participants now, 8 under way, none of them phase 3. Radiation Injuries · Italy.
Among the 12 studies in Radiation Injuries with a site in Italy, this one is the 5th largest by planned enrollment of the 10 observational ones that give a count, is the only one that started in 2020, is one of 10 observational ones, and was the 10th registered.
328 studies on the registry are indexed under Radiation Injuries; 96 are open to participants now.
Browse Radiation Injuries studies →7 of the 12 studies in Radiation Injuries with a site in Italy are open now. Recruiting first, the newest first:
Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Sites in Italy
Ages 18+
IRCCS San Raffaele · Sites in Italy
Ages 18–90 · Women only
CNAO National Center of Oncological Hadrontherapy · Sites in Italy
University of Milano Bicocca · Sites in Italy
Ages 18–90 · Men only
European Institute of Oncology · Sites in Italy
Ages 18+
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 76 Radiation Injuries studies recruiting now, 52 (68%) set no upper age limit and 14 (18%) stop at 75 or younger; 8 take children under 18; 2 take healthy volunteers.
This study: all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 1 started in 2020.
This study's planned enrollment of 280 is above the median of 130 across 96 observational studies indexed under Radiation Injuries.
Median enrollment 27 across the 2 interventional studies, 220 across the 10 observational. Of the 3 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 12 has an industry lead sponsor. The 10 most frequent:
Centro di Riferimento Oncologico - Aviano is the lead sponsor of 51 studies on the registry; 36 are open to participants now.
Centro di Riferimento Oncologico - Aviano has 1 study filed under Radiation Injuries — fewer than ten, so there is no comparison to draw.
2 of the studies in Radiation Injuries with a site in Italy that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06306170IRCCS San RaffaeleAdvanced Radiotherapy (ART) in Gynecological Cancer Patients (GYN-ART) | 2027-02-15 |
| NCT07129525Fondazione Policlinico Universitario Agostino Gemelli IRCCSHealth Oriented Protocol for Epidermal Radiodermatitis | 2027-03-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 12 studies in Radiation Injuries with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Radiotherapy key role in pediatric oncology, despite the potential side effects especially in the long term, including the risk of radioinduced second cancers.
Very rarely malignant neoplasms typical of children and adolescents may present in adulthood, historically with a worse outcome, but for some of these histologies demonstrated recent results overlapping with those in pediatric age when treated with strategies similar to pediatric protocols and similar radiotherapy.
Long-term data on outcome and incidence of potential toxicity late radiation therapy in these populations almost exclusively from epidemiologic studies or retrospective case series. Prospective data are lacking, particularly in patients treated with IMRT and specifically with certain IMRT modalities such as Helical Tomotherapy, for which the CRO pediatric radiotherapy has documented experience. The main objective is to evaluate the short- and long-term toxicity secondary to radiotherapy performed at the Pediatric Radiotherapy of the CRO in Aviano, with specific subgroup analyses aimed at highlighting any differences mainly by age, pathology and radiotherapy technique.
Radiotherapy key role in pediatric oncology, despite the potential side effects especially in the long term, including the risk of radioinduced second cancers.
Very rarely malignant neoplasms typical of children and adolescents may present in adulthood, historically with a worse outcome, but for some of these histologies demonstrated recent results overlapping with those in pediatric age when treated with strategies similar to pediatric protocols and similar radiotherapy.
Long-term data on outcome and incidence of potential toxicity late radiation therapy in these populations almost exclusively from epidemiologic studies or retrospective case series. Prospective data are lacking, particularly in patients treated with IMRT and specifically with certain IMRT modalities such as Helical Tomotherapy, for which the CRO pediatric radiotherapy has documented experience.
The main objective is to evaluate the short- and long-term toxicity secondary to radiotherapy performed at the Pediatric Radiotherapy of the CRO in Aviano, with specific subgroup analyses aimed at highlighting any differences mainly by age, pathology and radiotherapy technique.
All pediatric, adolescent and young adult (\<25 years old) patients with malignant neoplasm e All adult patients (≥25 years) with malignant neoplasm with histology typical of pediatric age but also rarely found in adults and typically treated wherever possible in pediatric protocols (mainly: malignant tumors affecting the central nervous system such as medulloblastomas and other embryonal tumors, ependymomas, and tumors with germ cells; soft tissue and bone sarcomas such as rhabdomyosarcomas and Ewing's sarcomas; nephroblastomas; neuroblastomas) undergoing radiation treatment at the pediatric radiation therapy of the CRO of Aviano
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Incidence of acute radiotherapy-related side effects
Cumulative incidence of acute side effects, with degree of individual toxicities encountered defined according to the most up-to-date version of the Common Terminology Criteria for Adverse Events (CTCAE) available at the time of analysis; analysis by subgroups of patients.
Time frame: up to 10 years
Incidence of chronic side effects related to radiotherapy
Cumulative incidence of chronic side effects, with degree of the individual toxicities encountered defined according to the most up-to-date version of the CTCAE available at the time of analysis; analysis by subgroups of patients
Time frame: up to 10 years
Incidence of second cancers
Cumulative incidence of second cancers; analysis by subgroups of patients.
Time frame: up to 10 years
Patient survival in terms of overall survival (OS, overall survival) and progression-free survival (PFS, progression-free survival)
Data will be summarized with survival curves according to Kaplan-Meier method; differences between selected subgroups of patients will be assessed by log-rank test. OS will be defined as time from beginning of the therapy until death from any cause or end of follow-up, whichever comes first.
Time frame: up to 10 years
Adequacy of radiation treatment understood as compliance with the requirements in terms of target coverage
Frequency of patient with adequate target coverage
Time frame: up to 10 years
Adequacy of radiation treatment understood as dose conformation to the target
Frequency of patient with adequate dose conformation to the target selection of alternative plans deemed superior and/or developed retrospectively with new radiotherapy techniques not yet available at the initial planning stage; qualitative-quantitative dosimetric comparisons between plans
Time frame: up to 10 years
Homogeneity of dose to the target
Frequency of patient with homogeneity of dose to the target
Time frame: up to 10 years
Started Oct 2020 (actual). Primary completion is estimated for Sep 2030, 119 months after the start.
Of 55 observational studies under Radiation Injuries, half reached primary completion within 74 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 189. This study's planned 119 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Centro di Riferimento Oncologico - Aviano